ALK
25 programs · 23 companies
Programs
25
Companies
23
Active Trials
15
Targeting ALK
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | CLLSCLC | |
| GSK-6983 | GSK | Phase 2 | SchizophreniaPTSD | |
| BAY-3308 | Bayer | Phase 1 | RettParkinson's | |
| Tixarelsin | Vertex Pharma | Phase 1 | Wilms | |
| VRT-6833 | Vertex Pharma | Preclinical | EoE | |
| Niralucimab | Ionis | Phase 1 | BCCNB | |
| 180-6098 | Innovent Bio | Phase 1 | Heart FailureNMOSD | |
| BEA-4274 | Beam | Phase 1/2 | Schizophrenia | |
| NVA-5991 | Novavax | Phase 1 | Ewing Sarcoma | |
| MSK-IIT-346 | MSKCC Breast Svc | Phase 2 | PAH | |
| MSK-IIT-373 | MSKCC Breast Svc | NDA/BLA | ALL | |
| Rilunaritide | Tenaya | Phase 1 | Atopic DermRA | |
| Tirazanubrutinib | Flagship Labs | Phase 1 | RACKD | |
| Motaderotide | Forma Therapeutics | Phase 2/3 | Pancreatic Ca | |
| COR-8406 | Correvio (Advanz) | Phase 2 | SLEParkinson's | |
| Zanufotisoran | Neumedicines | Phase 1/2 | DLBCLTTR Amyloidosis | |
| Zanuinavolisib | Verona Pharma | Phase 2 | Meso | |
| Lirainavolisib | BioVie | Approved | CML | |
| Pemiratamab | Yuhan Corp | Phase 2 | MigraineProstate Ca | |
| AMB-4811 | Ambys Med | Preclinical | SchizophreniaProstate Ca | |
| PBL-710 | Panbela | Approved | Alzheimer'sIgAN | |
| Sotoglumide | Zhejiang Medicine | Phase 1/2 | Angelman | |
| RIC-2161 | Gedeon Richter | Phase 2/3 | Wet AMDT2D | |
| VEE-8520 | Veeva Systems | NDA/BLA | NASHFabry | |
| Ivotenlimab | PathAI | Approved | PsA |